1. The value of genomic profiling in CNS tumors

      In the current era of personalized medicine, genomic profiling of central nervous system (CNS) tumors has gained much attention in the recent years in an effort to improve outcomes and provide targeted therapies. Despite many advances in cancer treatment, CNS tumors remain difficult to treat based on their suboptimal response to conventional therapies. In addition, they often lead to neurocognitive deficits necessitating a novel approach to both management and treatment of these tumors. Moreover, advances of genomic technologies, the current WHO (2016) reclassification of CNS tumors based on combination of molecular and histological data, and the knowledge that chromosomal aberrations drive tumorigenesis have all led to an increase in the value of genomic profiling in these tumors (including DNA copy number aberrations, structural chromosomal rearrangements and single nucleotide variants). In this presentation, we will discuss several cases of pediatric and adult CNS tumors (high grade gliomas, meningiomas, and embryonal tumors) in which genomic profiling provided improved classification, prognosis, as well as treatment options.
      To read this article in full you will need to make a payment


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect